Related Experiment Video
Updated: Jul 12, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
The pathophysiologic role of incretins
1Division of Endocrinology and Metabolism at the Philadelphia College of Osteopathic Medicine, 4190 City Ave, Suite 324, Philadelphia, PA 19131-1626, USA. jeffreyfreemando@aol.com
Many type 2 diabetes patients struggle with glycemic control. New incretin mimetics and dipeptidyl peptidase IV inhibitors improve blood sugar and HbA1c levels, offering a promising treatment option.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) affects millions, with many failing to reach glycemic targets.
- The American Diabetes Association recommends a hemoglobin A1c (HbA1c) below 7% for optimal T2DM management.
- Incretins, like GLP-1 and GIP, are crucial for insulin secretion but are rapidly degraded.
Purpose of the Study:
- To evaluate the role of incretin mimetics and dipeptidyl peptidase IV (DPP-IV) inhibitors in T2DM treatment.
- To assess the impact of these agents on glycemic control and HbA1c levels.
Main Methods:
- Review of incretin mimetic and DPP-IV inhibitor mechanisms of action.
- Analysis of clinical data on glycemic profiles and HbA1c changes post-administration.
Main Results:
- Incretin mimetics and DPP-IV inhibitors enhance incretin activity by preventing degradation.
- Administration of these drugs leads to improved postprandial glucose levels.
- Significant improvements in overall HbA1c were observed in patients treated with these agents.
Conclusions:
- Incretin mimetics and DPP-IV inhibitors represent a valuable therapeutic class for T2DM.
- These medications offer a clinically significant approach to achieving better glycemic control in T2DM patients.
More Related Videos
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl Peptidase 4 Inhibitors
Insulin Secretory Vesicles
Insulin: The Receptor and Signaling Pathways